Zhou Chuanbin, Gu Meijuan, Yin Lei, Yin Weifang, Liu Jie, Zhu Yongyun, Yin Kangfu, Lei Chunyan, Xu Zhong, Yang Xinglong
Department of Geriatric Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Department of Geriatric Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China; Yunnan Provincial Clinical Research Center for Neurological Disease, Kunming, 650032, Yunnan, China.
Sleep Med. 2023 May;105:9-13. doi: 10.1016/j.sleep.2023.03.011. Epub 2023 Mar 8.
Sleep disorders are common non-motor symptoms in patients with Parkinson's disease (PD). However, the pathogenesis of sleep disorders in PD patients remains unclear. Previous studies have implicated oxidative stress in sleep disorders associated with PD. Considering uric acid (UA) acts as a natural antioxidant, in this study, we aimed to assess the use of serum UA as a potential biomarker of sleep disorder in PD patients.
This study recruited 149 PD patients and 84 Age- and sex-matched individuals. According to the Pittsburgh Sleep Quality Index (PSQI) score, PD patients were divided into three groups, good (≤5), intermediate (6-10), and poor (>10). Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were also performed to identify clinical features and serum UA levels that help establish an accurate diagnostic model for poor sleep quality in PD patients.
PD patients who experienced poor sleep quality had lower serum UA levels. PSQI scores have significant negative relationships with serum UA levels and significant positive relationships with Hamilton Depression Scale (HAMD) scores in PD. Poor sleep quality was independently associated with serum UA levels and HAMD scores. A serum UA level of 328.7 μmol/L and HAMD scores of 19.5 could distinguish PD patients with poor or intermediate sleep to a certain extent, sensitivity of 79.4% and specificity of 76.6%.
Low serum UA levels may correlate with the severity of sleep disorder in PD patients and may serve as a biomarker for poor sleep quality in PD.
睡眠障碍是帕金森病（PD）患者常见的非运动症状。然而，PD患者睡眠障碍的发病机制仍不清楚。先前的研究表明氧化应激与PD相关的睡眠障碍有关。鉴于尿酸（UA）是一种天然抗氧化剂，在本研究中，我们旨在评估血清UA作为PD患者睡眠障碍潜在生物标志物的用途。
本研究招募了149例PD患者和84例年龄及性别匹配的个体。根据匹兹堡睡眠质量指数（PSQI）评分，将PD患者分为三组，良好（≤5分）、中等（6 - 10分）和较差（>10分）。还进行了多因素逻辑回归和受试者工作特征（ROC）曲线分析，以确定有助于建立PD患者睡眠质量差的准确诊断模型的临床特征和血清UA水平。
睡眠质量差的PD患者血清UA水平较低。在PD患者中，PSQI评分与血清UA水平呈显著负相关，与汉密尔顿抑郁量表（HAMD）评分呈显著正相关。睡眠质量差与血清UA水平和HAMD评分独立相关。血清UA水平为328.7μmol/L和HAMD评分为19.5在一定程度上可以区分睡眠质量差或中等的PD患者，敏感性为79.4%，特异性为76.6%。
血清UA水平低可能与PD患者睡眠障碍的严重程度相关，并且可能作为PD患者睡眠质量差的生物标志物。
